Home » Newsletters » BioWorld Science

BioWorld Science

April 4, 2016

View Archived Issues

XT-150 as a potential solution for opioid abuse crisis

Array BioPharma and Asahi Kasei Pharma establish strategic collaboration in pain and inflammation

Morphotek and AREVA Med to investigate ontuxizumab conjugated with lead-212

Astellas announces a new collaborative research agreement with AIST

Astellas and LEO Pharma announce the closing of transaction to transfer global dermatology business

Janssen discontinues phase III development of fulranumab for osteoarthritis pain

Guizhou Bailing Group Pharmaceutical discloses alpha-glucosidase inhibitors

Active Biotech patents S100A9 inhibitors

Bristol-Myers Squibb presents peroxidase inhibitors

Eli Lilly develops PDE4B inhibitors

Calreticulin antibody useful in the assessment of bone marrow biopsies

Array BioPharma discontinues MILO study of binimetinib

Amicus' migalastat gets positive opinion from EMA for Fabry disease

EMA's CHMP backs approval of Trevicta for schizophrenia

Samsung Bioepis' infliximab biosimilar receives positive opinion in E.U.

Positive interim results obtained in phase III trial of masitinib in ALS

CHMP recommends approval of Strimvelis for ADA-SCID

BMS's acquisition of Padlock Therapeutics completed

Xilonix will undergo accelerated assessment in E.U.

APE1 and MTH1 may be useful biomarkers for the diagnosis of breast cancer

IXICO announces two milestones concerning its Parkinson's disease franchise

Meiji Seika Pharma receives marketing rights for Ultibro and Seebri from Novartis Pharma in Japan

EMA committee recommends approval of pandemic influenza vaccine

Bionomics begins phase I trial for BNC-101 in metastatic colorectal cancer

CHMP supports E.U. approval of daratumumab

Acetylon Pharmaceuticals reports HDAC6 inhibitors

New bromodomain inhibitor shows promising preclinical results

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...